Eton Pharmaceuticals Reports Second Quarter 2022 Financial Results

Rhea-AI Summary

Eton Pharmaceuticals reported Q2 2022 revenue of $7.4 million, a 139% increase from the previous year. The company completed the divestiture of its hospital products division, focusing solely on rare diseases. Key growth drivers included ALKINDI SPRINKLE®, which saw 293% year-over-year growth, and Carglumic Acid, with a 100% sequential increase in sales. The FDA approved Zonisade™, with a $5 million milestone payment expected upon launch. Net loss for the quarter was $1.6 million.

Positive

• Q2 2022 revenue surged to $7.4 million, up 139% from the previous year.
• ALKINDI SPRINKLE sales increased 293% year-over-year.
• Carglumic Acid sales grew 100% sequentially.
• Successfully divested hospital products division for up to $50 million.
• FDA approval of Zonisade™ expected to generate a $5 million milestone payment.

Negative

• Net loss was $1.6 million, slightly improved from a loss of $2.0 million in the prior year.
• General and administrative expenses increased to $5.3 million from $3.2 million in the prior year.

• Total Q2 2022 revenue of $7.4 million, up 139% from prior year
• Recently launched ALKINDI SPRINKLE^® and Carglumic Acid continue to show robust growth
• Divestiture of hospital products division to focus on rare disease strategy
• U.S. Food and Drug Administration (FDA) Approval of Zonisade™ (zonisamide oral suspension)

DEER PARK, Ill., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the second quarter ended June 30, 2022.

“The second quarter of 2022 was a critical inflection point for the company. With the completion of the hospital products divestiture, we are now 100% focused on our rare disease strategy and are well capitalized to execute on our mission to be a leading rare disease company. Sales of our recently launched ALKINDI SPRINKLE^® remain strong, with 293% year-over-year revenue growth, and feedback from the patient and physician communities continues to be overwhelmingly positive. Carglumic Acid also delivered another impressive quarter, with sales growing 100% sequentially. Physicians and patients appreciate the convenience of the room-temperature-stable product as well as the significant financial savings to the healthcare system compared to the competing product. We believe both products have long runways ahead of them and we are excited about the opportunities to add additional rare disease products to our portfolio this year,” said Sean Brynjelsen, CEO of Eton Pharmaceuticals.

Second Quarter and Recent Business Highlights

• Sold hospital products for up to $50 million, finalizing Eton’s transition to a dedicated rare disease company. In June, Eton sold Biorphen^®, Rezipres^®, and Cysteine Hydrochloride to Dr. Reddy’s Laboratories, allowing Eton to focus solely on its rare disease product portfolio.
  
  
• Reported sixth straight quarter of sequential growth in product sales and royalty revenue. For the second quarter of 2022, Eton reported total revenue of $7.4 million, an increase of 139% over the prior year period. Product sales and royalty revenue were $2.4 million during the quarter, an increase of 316% over the prior year period.
  
  
• Continued growth in ALKINDI SPRINKLE^®. ALKINDI SPRINKLE sales grew 293% over the second quarter of 2021 and 34% over the first quarter of 2022, demonstrating a strong desire for the low-dose treatment options that ALKINDI SPRINKLE offers.
  
  
• Strong adoption of Carglumic Acid tablets. Carglumic Acid sales in the second quarter of 2022 grew 100% over the first quarter of 2022. Physicians and patients continue to appreciate the convenience of Eton’s room-temperature-stable product and the significant financial savings that the product delivers to the U.S. healthcare system relative to the competing product.
  
  
• FDA Approval of Zonisade™ (zonisamide oral suspension). In July, Zonisade was approved by the FDA. Azurity Pharmaceuticals will be solely responsible for commercializing the product and Eton will receive a $5 million milestone payment upon launch and an ongoing royalty on commercial sales.
  
  
• Progressed R&D pipeline to support additional new product launches in coming years. During the quarter, the company made progress addressing the FDA’s requests on dehydrated alcohol injection and expects to resubmit the application for the product later this year, which could allow for approval and launch of the product in 2023. The company continues to progress development of ZENEO^® hydrocortisone autoinjector, which could be filed with the FDA in 2023. In addition, the company has initiated development of two additional high-value rare disease products.
  

Second Quarter Financial Results

Net Sales: Net sales for the second quarter of 2022 were $7.4 million compared with $3.1 million in the prior year period. Net sales included $5.0 million of licensing payments related to the sale of the hospital products division to Dr Reddy’s Laboratories during the quarter, and $2.5 million of licensing payments related to the Azurity Pharmaceuticals transaction in the second quarter of 2021.

Product sales and royalty revenue were $2.4 million for the second quarter of 2022 compared with $0.6 for the second quarter of 2021. Product sales and royalty revenue in the second quarter of 2022 were negatively impacted by a $0.2 million inventory allowance adjustment resulting from the divestiture of Rezipres^®. Excluding the impact of this adjustment, product sales and royalty revenue would have increased 351% over the prior year period and 18% over the first quarter of 2022. The increase in product sales and royalty revenue was primarily driven by growth in ALKINDI SPRINKLE and the launch of Carglumic Acid tablets.

Gross Profit: Gross profit for the second quarter of 2022 was $4.6 million compared with $2.9 million in the prior year period. Gross profit for the second quarter of 2022 included $1.8 million of non-cash expenses related to the divestment of the hospital products. The growth was primarily due to increased licensing income, growth in ALKINDI SPRINKLE, and the launch of Carglumic Acid tablets.

General, and Administrative (G&A) Expenses: G&A expenses for the second quarter of 2022 were $5.3 million compared to $3.2 million in the prior year period. Cash G&A expenses for the second quarter of 2022 were $3.9 million, compared to $2.9 million in the prior year period. The increase in cash SG&A expenses was primarily driven by increased employee expenses and increased sales and marketing expenses to support the growth of the company’s commercial products.

Research & Development (R&D) Expenses: R&D expenses for the second quarter of 2022 were $0.7 million compared to $2.0 million in the prior year period. The prior year period included a $0.5 million milestone payment related to the company’s ZENEO hydrocortisone autoinjector.

Net Income/Loss: Net income for the second quarter of 2022 was a loss of $1.6 million or $0.06 per basic and diluted share compared to a loss of $2.0 million or $0.08 per basic and diluted share in the prior year period.

Cash Position: As of June 30, 2022, the company had cash of $17.0 million. The company is entitled to receive an additional $5.0 million milestone payment upon the launch of the recently approved Zonisade™ product.

Conference Call and Webcast Information:
As previously announced, Eton Pharmaceuticals will host its second quarter 2022 conference call as follows:

Date	August 11, 2022
Time	4:30 p.m. ET (3:30 p.m. CT)
Toll Free (U.S).)	1-800-715-9871
International	1-646-307-1963
Conference ID	9229889

The webcast can be accessed under “Events & Presentations” in the Investors section of the company’s website at https://ir.etonpharma.com. The webcast will be archived and made available for replay on the company’s website approximately two hours after the call and will be available for 30 days.

Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with the expected ability of Eton to undertake certain activities and accomplish certain goals and objectives. These statements include but are not limited to statements regarding Eton’s business strategy, Eton’s plans to develop and commercialize its product candidates, the safety and efficacy of Eton’s product candidates, Eton’s plans and expected timing with respect to regulatory filings and approvals, and the size and growth potential of the markets for Eton’s product candidates. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Eton’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. These and other risks concerning Eton’s development programs and financial position are described in additional detail in Eton’s filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Eton undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

About Eton Pharmaceuticals
Eton Pharmaceuticals, Inc. is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The company currently commercializes ALKINDI SPRINKLE^® and Carglumic Acid tablets and has two additional rare disease products under development, dehydrated alcohol injection and the ZENEO^® hydrocortisone autoinjector. In addition, the company is entitled to receive milestone payments or royalties on seven different products.

Eton Pharmaceuticals, Inc.
Condensed Statements of Operations
(In thousands, except per share amounts)
(Unaudited)

	For the three months ended								For the six months ended
	June 30,				June 30,				June 30,				June 30,
	2022				2021				2022				2021
Revenues:
Licensing revenue	$	5,000			$	2,500			$	5,000			$	14,000
Product sales and royalties		2,358				567				4,534				964
Total net revenues		7,358				3,067				9,534				14,964
Cost of sales:
Licensing revenue		990				—				990				1,500
Product sales and royalties		1,755				174				2,604				301
Total cost of sales		2,745				174				3,594				1,801
Gross profit		4,613				2,893				5,940				13,163
Operating expenses:
Research and development		690				1,990				2,308				2,876
General and administrative		5,263				3,228				10,059				7,249
Total operating expenses		5,953				5,218				12,367				10,125
(Loss) income from operations		(1,340	)			(2,325	)			(6,427	)			3,038
Other (expense) income:
Interest and other expense, net		(218	)			(237	)			(461	)			(484	)
Gain on PPP loan forgiveness		—				365				—				365
Gain on equipment sale		—				181				—				181
(Loss) income before income tax expense		(1,558	)			(2,016	)			(6,888	)			3,100
Income tax expense		—				—				—				—
Net (loss) income	$	(1,558	)		$	(2,016	)		$	(6,888	)		$	3,100
Net loss (income) per share, basic	$	(0.06	)		$	(0.08	)		$	(0.28	)		$	0.12
Net loss (income) per share, diluted	$	(0.06	)		$	(0.08	)		$	(0.28	)		$	0.12
Weighted average number of common shares outstanding, basic		25,126				25,211				24,915				25,133
Weighted average number of common shares outstanding, diluted		25,126				25,211				24,915				26,486

Eton Pharmaceuticals, Inc.
Condensed Balance Sheets
(in thousands, except share and per share amounts)

	June 30, 2022				December 31, 2021
	(Unaudited)
Assets
Current assets:
Cash and cash equivalents	$	17,046			$	14,406
Accounts receivable, net		834				5,471
Inventories		531				550
Prepaid expenses and other current assets		1,365				3,177
Total current assets		19,776				23,604
Property and equipment, net		87				115
Intangible assets, net		3,108				3,621
Operating lease right-of-use assets, net		63				104
Other long-term assets, net		12				21
Total assets	$	23,046			$	27,465
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	$	1,299			$	1,774
Current portion of long-term debt		364				1,418
Accrued liabilities		2,149				1,366
Total current liabilities		3,812				4,558
Long-term debt, net of discount and including accrued fees		5,992				5,262
Operating lease liabilities, net of current portion		—				15
Total liabilities		9,804				9,835
Commitments and contingencies (Note 11)
Stockholders’ equity
Common stock, $0.001 par value; 50,000,000 shares authorized; 25,272,037 and 24,626,004 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively		25				25
Additional paid-in capital		114,218				111,718
Accumulated deficit		(101,001	)			(94,113	)
Total stockholders’ equity		13,242				17,630
Total liabilities and stockholders’ equity	$	23,046			$	27,465

Eton Pharmaceuticals, Inc.
Condensed Statements of Cash Flows
(In thousands)
(Unaudited)

	Six months ended June 30, 2022				Six months ended June 30, 2021
Cash flows from operating activities
Net (loss) income	$	(6,888	)		$	3,100
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Stock-based compensation		2,383				1,509
Depreciation and amortization		1,352				240
Debt discount amortization		66				73
Gain on forgiveness of debt		—				(365	)
Gain on sale of equipment		—				(181	)
Changes in operating assets and liabilities:
Accounts receivable		4,637				(255	)
Inventories		19				—
Prepaid expenses and other assets		1,827				419
Accounts payable		(475	)			(822	)
Accrued liabilities		763				(372	)
Net cash provided by operating activities		3,684				3,346
Cash (used in) provided by investing activities
Proceeds from sale of equipment		—				700
Purchase of product license rights		(750	)			—
Purchases of property and equipment		(26	)			(3	)
Net cash (used in) provided by investing activities		(776	)			697
Cash flows from financing activities
Repayment of long-term debt		(385	)			—
Proceeds from employee stock option exercises and ESPP		117				464
Net cash (used in) provided by financing activities		(268	)			464
Change in cash and cash equivalents		2,640				4,507
Cash and cash equivalents at beginning of period		14,406				21,295
Cash and cash equivalents at end of period	$	17,046			$	25,802
Supplemental disclosures of cash flow information
Cash paid for interest	$	378			$	424

Investor Contact:
David Krempa
dkrempa@etonpharma.com
612-387-3740

FAQ

What were Eton Pharmaceuticals' Q2 2022 financial results?

Eton Pharmaceuticals reported Q2 2022 revenue of $7.4 million, a 139% increase year-over-year.

How did sales of ALKINDI SPRINKLE® perform in Q2 2022?

ALKINDI SPRINKLE® sales grew 293% compared to Q2 2021.

What is the significance of the Zonisade™ FDA approval for Eton Pharmaceuticals?

The FDA approval of Zonisade™ allows Eton to receive a $5 million milestone payment upon launch.

What was Eton's net income in Q2 2022?

Eton reported a net loss of $1.6 million for Q2 2022.

How did Eton Pharmaceuticals' Carglumic Acid perform in the second quarter?

Carglumic Acid sales grew 100% sequentially in Q2 2022.